Company Overview
MARAbio Systems, Inc. (MARAbio) is a precision immunology company with proprietary technology related to a distinct cluster of autoantibodies that lead to Maternal Autoantibody Related Autism (MARA) or MAR-Autism.
As detailed in numerous peer-reviewed scientific manuscripts, MARA is an immune system-mediated subtype of autism that is currently estimated to represent up to 20% of autism diagnoses.
Research shows MARA autoantibodies are associated with both moderate and more severe autistic symptoms in the child.
MARAbio is working with care providers to enable early interventions, tailor approaches and specific strategies for better outcomes. We firmly believe early detection coupled with targeted intervention and development of specialized therapeutics will improve the lives of individuals with MARA and their families, while also reducing the burden of care.
Our precision technology uses a blood test in women either prior to pregnancy or as early as birth to identify the presence of a distinct cluster of antibodies that lead to the MARA subtype of autism.
This technology provides MARAbio with a unique threefold differentiation:
MAR-Autism test for mothers:
with a previous child diagnosed with autism, to give families answers in younger siblings or prior to future pregnancies and/or
with a child showing signs of autism, enabling earlier referral for diagnostic evaluation and treatment
Companion diagnostic test:
for the supplemental indication of FDA-approved therapeutic interventions, including anti-FcRn blocking antibodies
Learn more about the MAR-Autism Test at www.marautism.com
Proprietary therapeutic antibody interventions:
targeted against the MARA-specific autoantibodies to mitigate the effects of MARA
Ultimately, knowing if a child has the MAR-Autism subtype may help behavioral therapists tailor their intervention approaches for better outcomes. Additional indications include pre-conception testing, which is particularly useful for women that are at high likelihood of having an autistic child, and potential therapeutics to reduce the likelihood of a child having MARA.
Please note: The test is not intended or validated for use during pregnancy until treatment is available.
The MAR-Autism test can accelerate the diagnosis of autism and initiation of intervention for children whose mothers test positive. Early behavioral intervention therapy is widely recognized to have a positive impact on quality of life for individuals with autism.
Knowing helps therapists and interventionists tailor their care and approach to serving those with MAR-Autism and their families to improve outcomes.
